Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
Last trade$0.8373
Day change+$0.0144 (+1.75%)
Day range$0.7982 – $0.892
Volume40,318
Market cap$37M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$36.41M
Price / earnings
0.67×
Price / book
2.38×
Price / sales
3.66×
EV / sales
1.55×
EV / EBITDA
-0.68×
Profitability
Earnings per share
$1.23
Return on assets
112.86%
Return on equity
354.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.53×
Current ratio
2.63×
Quick ratio
2.61×
Cash ratio
1.81×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$50.68M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ELUT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.14M
$2.43M
$3.11M
$3.27M
$944K
$2.75M
$2.95M
$2.82M
Cost of revenue
$435K
$980K
$1.31M
$1.36M
$446K
$1.29M
$1.57M
$1.49M
Gross profit
$702K
$1.45M
$1.8M
$1.91M
$498K
$1.45M
$1.38M
$1.32M
Selling, general and administrative
$4.5M
$4.82M
$5.57M
$6.19M
$4.43M
$4.83M
$4.72M
$5.44M
Research and development
$2.98M
$2.53M
$1.97M
$1.22M
$1.09M
$989K
$871K
$727K
Total operating expenses
$7.6M
$9.4M
$8.15M
$8.48M
$6.37M
$9.82M
$8.16M
$8.78M
Operating income
-$6.9M
-$7.96M
-$6.35M
-$6.56M
-$5.87M
-$8.37M
-$6.78M
-$7.46M
Interest expense
-$278K
$35K
$0
-$42K
-$265K
$491K
$0
$796K
Income before taxes
-$6.5M
-$7.64M
-$7.82M
-$6.52M
-$1.04M
-$7.08M
-$1.88M
-$7.15M
Income taxes
$8K
$8K
$70K
-$11K
$8K
$8K
$8K
$2K
Net income
-$1.29M
-$7.65M
-$7.47M
$70.79M
-$3.87M
-$9.61M
-$3.93M
-$9.06M
Net income attributable to common shareholders
-$1.29M
-$7.65M
-$7.47M
$70.79M
-$3.87M
-$9.61M
-$3.93M
-$9.06M
EBITDA
-$6.38M
-$5.55M
-$5.41M
-$5.19M
-$4.29M
-$3.47M
-$3.34M
-$3.98M
Basic earnings per share
-$0.03
-$0.17
-$0.17
$1.65
-$0.09
-$0.23
-$0.10
-$0.26
Diluted earnings per share
-$0.04
-$0.17
-$0.17
$1.49
-$0.19
-$0.26
-$0.21
-$0.28
Recent news
Company coverage with links to the original publishers.
Elutia Inc. (Nasdaq: ELUT) announced the grant of 460,000 non-qualified stock options to three new employees as inducement awards on March 10, 2026, with an exercise price of $1.09 per share. The options vest 25% after one year, with the remainder vesting monthly over three years, subject to continued employment.
Elutia sold its BioEnvelope business to Boston Scientific for $88 million, allowing the company to focus on developing NXT-41x, a biomatrix technology for breast reconstruction with potential to address serious surgical complications.
SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company’s Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $13.26 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about June 18, 2024, subject to customary closing conditions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.